Alhar_2025_J.Diabetes.Res_2025_8050374

This study explores the potential of curcumin (CUR), extracted from Curcuma longa, in combating obesity and Type 2 diabetes. Obesity and Type 2 diabetes were induced in rats through a high-fat and high-fructose diet (HFFD), and CUR, after purification and characterization by Fourier transform infrared spectroscopy (FTIR) and ultraviolet (UV) spectroscopy, was administered for 3 months via gastric gavage. The results show that CUR supplementation activates the insulin signaling pathway in a dose-dependent manner, leading to improved insulin sensitivity. Specifically, administering CUR at a daily dose of 100 mg/kg significantly reduces the activities of protein tyrosine phosphatase (PTP1B) and dipeptidyl peptidase-4 (DPP-4) by 43% and 45%, respectively, in obese and Type 2 diabetic rats compared to untreated obese rats. Furthermore, CUR effectively inhibits lipase and alpha-amylase activities at both the serum and intestinal levels. In obese rats, CUR administration reduces glycogen phosphorylase (GP) activity by 35% and enhances glycogen synthase (GS) activity by 78%, leading to a substantial increase in hepatic glycogen content. Additionally, CUR also led to a 21% reduction in food intake and a 12% decrease in water consumption. These changes contributed to significant reductions in the blood sugar and glycosylated hemoglobin (HbA1c) levels, with decreases of 59% and 53%, respectively. Additionally, administering CUR at a dose of 100 mg/kg body weight reduced thiobarbituric acid reactive substances (TBARSs), hydrogen peroxide (H(2)O(2)), and total oxidant status (TOS) in obese and diabetic rats, with reductions of 49%, 59%, and 58%, respectively. Furthermore, CUR demonstrates a strong regulatory effect on the levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and total cholesterol (TC). Overall, these results underscore the CUR potential for treating and preventing diabetes and obesity.